NCT03206177View on ClinicalTrials.gov

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

July 28, 2021

Study Completion Date

February 13, 2024

Conditions
Carcinosarcoma, Ovarian
Interventions
DRUG

Galunisertib

Galunisertib 150mg po BID day 4-17

DRUG

Paclitaxel

IV Day 1: Paclitaxel 175 mg/m2 over 3 hours

DRUG

Carboplatin

IV Day 1: Carboplatin AUC 6\* over 1 hour (or 5\* if prior radiation therapy)

Trial Locations (1)

73104

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Oklahoma

OTHER

NCT03206177 - Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | Biotech Hunter | Biotech Hunter